SOURCE: Stem Cell Therapy International, Inc.

October 27, 2005 06:00 ET

Stem Cell Therapy International Announces the Successful Treatment of Stroke Victim Who Received Stem Cell Transplantation Therapy

Company Posts Video Clip on Web Site Demonstrating Results

TAMPA, FL -- (MARKET WIRE) -- October 27, 2005 -- Stem Cell Therapy International, Inc. (OTC: SCII), a leading company in the field of research and development of stem cell transplantation (SCT) therapy and regenerative medicine, announced today the successful results of a case of stem cell transplantation recently concluded in Kiev, Ukraine, on Ian McBride, 49, a stroke victim from Belfast, Ireland.

Mr. McBride, a former porter in the City Hospital in Belfast, Ireland, whose left arm and left leg were paralyzed as a result of a stroke 18 months ago, had undergone traditional treatment for stroke victims in various clinics and hospitals in Ireland. His doctors held out no hope that Mr. McBride could recover mobility in these limbs.

Calvin Cao, CEO of Stem Cell Therapy International, said that after his disappointing diagnosis, Mr. McBride began searching for alternative medical procedures. Mr. McBride visited our website and decided that the use of stem cells to treat his condition may be the solution he was looking for. SCTI arranged for Mr. McBride to travel to Kiev to be treated with injections of embryonic stem cells at the Institute of Cell Therapy in September. As a result of the transplantation of stem cells into his body, Mr. McBride can now lift and bend his left leg and can move his left arm, as well as grip the side of the bed or someone's hand with his left hand and was able to sit up on his own. Something he was unable to do since he suffered the stroke.

SCTI has posted a Video Clip on its web site made in Kiev by Mr. Cao himself, after Mr. McBride's treatment that shows his remarkable improvement. In the Video Clip, listeners can clearly see Mr. McBride demonstrate his left side mobility and hear him testify as to the results of the therapy.

Mr. Cao said, "We are very excited about the improvement in Ian McBride's condition as a result of the stem cell therapy he received at the clinic. The procedure is based on the technology of the biological solution used, which is part of the exclusive license agreement SCTI has for the use of the 26 patents related to stem cells from the Institute of Cell Therapy (ICT). This is the first case we have conducted since arranging our exclusive licensing agreement to distribute and use stem cell solutions to treat human patients and the results exceeded our expectations.

"In addition to posting the Video Clip demonstrating Mr. McBride's improvement on the Web site," Mr. Cao said, "we have asked Dr. Weiwen Deng, MD., Ph.D., an expert in stem cell therapy from Tulane University and a member of the SCTI Medical Advisory Board, to prepare a scientific abstract on the case and submit it to an appropriate scientific journal for publication. This case, we believe, will encourage stem cell researchers around the world to strengthen their efforts to gain acceptance for the widespread use of stem cell therapy."

Mr. McBride raised the funds needed to pay for the procedure with the help of donations from a fund set up by the Irish Sunday World newspaper.

Mr. Cao reported that at the suggestion of the SCTI Medical Advisory Board, Mr. McBride is scheduled to return to the clinic in Kiev in six months for additional stem cell transplantation therapy to help speed up the healing process of his entire body.

Stem cell transplantation therapy is a field of medicine which uses techniques and technologies that rely on replacing diseased, damaged or dysfunctional cells with healthy, functioning ones. This therapy is similar to the process of organ transplantation, only the treatment consists of the transplantation of stem cells into the body rather than entire organs, thus eliminating any chance of rejection or the need for expensive and potentially dangerous immunosuppression drug therapy. These new techniques are being applied to finding a cure for a wide range of human disorders, including neurological diseases such as Alzheimer's, Parkinson's Disease, ALS, (also commonly known as Lou Gehrig's disease), leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, diabetes as well as certain types of cancer and can be used to alleviate the side effects of chemotherapy.

With the enactment of Proposition 71 in California in November 2004, a fund of $3 billion was created to fund stem cell research. Since then four other states, New Jersey, Connecticut, Illinois and Wisconsin, have allocated funds for stem cell research. Among the leading public companies in the U.S. in the field of stem cell technology are Advanced Cell Technology, Inc.; ViaCel; Geron; StemCells, Inc.; and Aastrom Biosciences Inc. For additional information about SCTI's stem cell treatment procedures, you can visit their website @ www.scticorp.com.

About Stem Cell Therapy International (SCTI)

Stem Cell Therapy International, Inc. is a leader in the research and development field of regenerative medicine. SCTI provides stem cell solutions that are currently being used in the treatment of patients suffering from degenerative disorders of the human body. The Company has established agreements with highly specialized, professional medical treatment facilities around the world in locations where stem cell transplantation therapy is approved by the appropriate local government agencies. SCTI intends to provide these biological solutions containing stem cell products in the United States as well, to universities, institutes and privately funded laboratory facilities for research purposes and clinical trials. Their products, which are available now, include biological solutions containing embryonic stem cells, adult stem cells and stem cell which are extracted from umbilical cord blood.

Forward-Looking Statements

This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and pricing and general economic risks and uncertainties.

Contact Information

  • For more information, please contact:

    Stem Cell Therapy
    International
    Calvin C. Cao
    Chairman and CEO
    Stem Cell Therapy
    International
    T: 813-600-4088
    E: calvin@scticorp.com


    Investor Relations
    Arun Chakraborty
    Investor Relations
    Stern & Co.
    T: 212-888-0044
    E: achakrab@sternco.com

    Media Relations
    Stan Froelich
    VP, Media Relations
    Stern & Co.
    T: 212-888-0044
    E: sfroelich@sternco.com